

Resource Summary Report

Generated by NIF on Aug 1, 2026

APC anti-mouse CD137

RRID:AB_2564297

Type: Antibody

Proper Citation

BioLegend Cat# 106110, RRID:AB_2564297

Antibody Information

URL: http://antibodyregistry.org/AB_2564297

Proper Citation: BioLegend Cat# 106110, RRID:AB_2564297

Target Antigen: CD137

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD137

Description: This monoclonal targets CD137

Target Organism: mouse

Clone ID: Clone 17B5

Antibody ID: AB_2564297

Vendor: BioLegend

Catalog Number: 106110

Alternative Catalog Numbers: 106109

Record Creation Time: 20250819T230525+0000

Record Last Update: 20250820T041510+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD137.

No alerts have been found for APC anti-mouse CD137.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Uraki R, et al. (2025) An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant. EBioMedicine, 117, 105794.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine, 5(4), 101479.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Martin AL, et al. (2023) Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. Cancer immunology, immunotherapy : CII, 72(6), 1445.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med (New York, N.Y.), 4(5), 326.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).

Blomberg OS, et al. (2023) IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer cell, 41(1), 106.

Maruhashi T, et al. (2022) Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity, 55(5), 912.

Wang C, et al. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell reports, 37(8), 110021.

Hanna BS, et al. (2021) Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity,

54(12), 2825.

Sadik A, et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, 182(5), 1252.

Jin J, et al. (2020) CD137 Signaling Regulates Acute Colitis via RALDH2-Expressing CD11b-CD103⁺ DCs. *Cell reports*, 30(12), 4124.

Ettxeberria I, et al. (2019) Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8⁺ T Cells. *Cancer cell*, 36(6), 613.